Thymosin Alpha-1 + LL-37 + BPC-157: The Immune Restoration Stack
Thymosin Alpha-1
Thymic peptide enhancing T-cell maturation and adaptive immune function
LL-37
Human cathelicidin antimicrobial peptide for innate immune defence
BPC-157
Cytoprotective peptide supporting tissue repair and reducing inflammation
This three-peptide stack targets immune restoration from multiple angles: adaptive immunity (Thymosin Alpha-1), innate antimicrobial defence (LL-37), and tissue repair with anti-inflammatory support (BPC-157).
Thymosin Alpha-1 (Tα1) is the most clinically validated peptide in this stack, with approval in over 35 countries for hepatitis B and as an immune adjuvant. LL-37 is the only human cathelicidin — a broad-spectrum antimicrobial peptide that also modulates immune signalling. BPC-157 provides cytoprotective and anti-inflammatory support.
**Critical Disclaimer:** This combination has not been studied as a stack. Thymosin Alpha-1 is approved in some countries but not in the UK/EU for this indication. LL-37 and BPC-157 are research compounds. This content is educational only.
Synergistic Mechanism
Triple-Pathway Immune Synergy
Thymosin Alpha-1: Adaptive Immunity
- Promotes T-cell maturation and differentiation in the thymus
- Enhances dendritic cell function (antigen presentation)
- Increases NK cell activity
- Modulates cytokine production (balances Th1/Th2 response)
- Approved for hepatitis B in 35+ countries
LL-37: Innate Immunity
- Directly kills bacteria, fungi, and enveloped viruses via membrane disruption
- Modulates TLR signalling (bridges innate and adaptive immunity)
- Promotes wound healing and angiogenesis at infection sites
- Recruits immune cells to sites of infection
- Neutralises bacterial endotoxins (LPS)
BPC-157: Tissue Support
- Reduces inflammatory cytokines (TNF-α, IL-6)
- Promotes tissue repair in gut and other mucosal surfaces
- Supports angiogenesis for immune cell delivery
- Cytoprotective against various tissue insults
- May support gut-associated lymphoid tissue (GALT)
The Combined Logic
1. Tα1 strengthens the adaptive immune system (T-cells, NK cells)
2. LL-37 provides frontline antimicrobial defence
3. BPC-157 repairs damaged tissue and reduces excessive inflammation
4. Together: enhanced immune surveillance + antimicrobial defence + tissue recovery
Research Evidence
Research Evidence
Thymosin Alpha-1
- Approved medication in 35+ countries
- Phase II/III trials for hepatitis B, hepatitis C, and cancer immunotherapy adjunct
- Demonstrated T-cell enhancement and improved vaccine response in elderly populations
- COVID-19 studies showed potential benefit in critically ill patients
LL-37
- The only human cathelicidin — well-characterised antimicrobial spectrum
- Demonstrated efficacy against drug-resistant bacteria in vitro
- Wound healing studies show improved closure and reduced infection
- Immunomodulatory effects validated in multiple preclinical models
BPC-157
- Extensive preclinical data for anti-inflammatory and tissue repair effects
- Demonstrated cytoprotection across GI tract, tendons, muscles, and nervous system
- Limited human safety/efficacy data
Combination Evidence
No published studies examine this specific three-peptide combination.
We do not publish stack protocols
Peptide Authority does not publish doses, reconstitution recipes, injection schedules, or cycle lengths for combinations of unlicensed peptides. This is a deliberate editorial position — we are an evidence and risk-intelligence publisher, not a prescriber. The reasoning is set out in detail in our no dosing, no sourcing policy.
For an honest review of what proponents of this kind of combination claim versus what the published evidence actually supports, see the combination claim-reviews. If you are considering any peptide medicine, speak to a GMC-registered doctor or GPhC-registered pharmacist.
Expected Outcomes
Expected Research Outcomes
**Thymosin Alpha-1:** Enhanced T-cell counts and function, improved vaccine response, potential viral load reduction
**LL-37:** Antimicrobial support, potential reduction in recurrent infections
**BPC-157:** Reduced tissue inflammation, gut barrier support, general cytoprotection
Timeline:
- Weeks 1-2: Immune marker changes may begin (T-cell subsets)
- Weeks 3-4: Functional immune improvement may be observable
- Weeks 4-8: Full protocol effect period
Safety Considerations
Safety Considerations
- Thymosin Alpha-1: Well-characterised safety from clinical use; injection site reactions, rare flu-like symptoms
- LL-37: Theoretical concern about antimicrobial resistance with chronic use; limit duration
- BPC-157: Limited human safety data; generally well-tolerated in anecdotal reports
- Combined immune stimulation should be monitored — over-activation could theoretically worsen autoimmune conditions
- Contraindicated in active autoimmune disease without specialist supervision
- Blood work: CBC with differential, CRP, immunoglobulin levels
Frequently Asked Questions
Conclusion
The Thymosin Alpha-1 + LL-37 + BPC-157 stack represents a multi-pathway approach to immune restoration research, targeting adaptive immunity, innate defence, and tissue support simultaneously. Thymosin Alpha-1 is the most clinically validated component. This combination is theoretical and unstudied as a stack.